Back to Search
Start Over
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers.
- Source :
-
World journal of clinical oncology [World J Clin Oncol] 2011 Mar 10; Vol. 2 (3), pp. 158-63. - Publication Year :
- 2011
-
Abstract
- Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade. New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs. Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival, although the effect was minimal. Little or no improvement in survival with recent molecular-targeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer. Recently, the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time. For biliary tract cancer, gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy. Further improvement in survival is expected by the addition of cetuximab.
Details
- Language :
- English
- ISSN :
- 2218-4333
- Volume :
- 2
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- World journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 21611090
- Full Text :
- https://doi.org/10.5306/wjco.v2.i3.158